Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + chlorpheniramine is a small molecule combination drug developed by Sichuan Defeit Pharmaceutical for the symptomatic relief of cold and allergy symptoms in children. Marketed as Children's Acetaminophen/Chlorphenamine Granules (小儿氨酚黄那敏颗粒), the product is administered orally in granule form. It contains two active ingredients: acetaminophen (paracetamol), an analgesic and antipyretic that reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system, and chlorpheniramine (chlorphenamine), an antihistamine that blocks histamine H1 receptors to relieve symptoms such as sneezing, runny nose, and itching. The product is approved and available in China for pediatric use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + chlorpheniramine.